


=>

Uploading C:\Program Files\Stnexp\Queries\10789281a.str



chain nodes :

12 13 20 21 22

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18 19

chain bonds :

1-6 4-12 9-22 12-13 13-14 18-20 20-21

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 14-15 14-19 15-16  
16-17

17-18 18-19

exact/norm bonds :

1-5 4-5 12-13 13-14

exact bonds :

1-2 1-6 2-3 3-4 4-12 9-22 14-15 14-19 15-16 16-17 17-18 18-19 18-20  
20-21

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 : 6 : 14 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:CLASS 21:CLASS  
22:CLASS

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s 14 full

FULL SEARCH INITIATED 12:57:20 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 636 TO ITERATE

100.0% PROCESSED 636 ITERATIONS

28 ANSWERS

SEARCH TIME: 00.00.01


L5 28 SEA SSS FUL L4

L10      STRUCTURE UPLOADED

=> d

L10 HAS NO ANSWERS

L10                      STR



Structure attributes must be viewed using STN Express query preparation.

=> s l10 full

FULL SEARCH INITIATED 13:03:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -            517 TO ITERATE

100.0% PROCESSED            517 ITERATIONS


257 ANSWERS

SEARCH TIME: 00.00.01

L11                      257 SEA SSS FUL L10


L12 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN  
 ACCESSION NUMBER: 2006167981 CAPLUS  
 DOCUMENT NUMBER: 144:233064  
 TITLE: Preparation of 2-phenyloxazoles as peroxisome proliferator agonist  
 INVENTOR(S): Glombik, Heiner; Stapper, Christian; Falk, Eugen; Keil, Stefanie; Schaefer, Hans-Ludwig; Wendler, Wolfgang; Knieps, Stephanie  
 PATENT ASSIGNEE(S): Sanofi-Aventis Deutschland G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 74 pp.  
 DOCUMENT TYPE: Patent: PIXXD2  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018118	A1	20060223	WO 2005-EP8284	20050730
WO 2006018118	A8	20060519		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
DE 102004039533	A1	20060302	DE 2004-102004039533	20040814
DE 102004039533	B4	20060928		
PRIORITY APPLN. INFO.:			DE 2004-102004039533A	20040814
OTHER SOURCE(S):	MARPAT 144:233064			
GI				




II

L12 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 876586-77-5 CAPLUS  
 CN Propanoic acid, 2-[[[(1S,3R)-3-[[[2-(3,4-dimethylphenyl)-5-ethyl-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876586-78-6 CAPLUS  
 CN Propanoic acid, 2-[[[(1S,3R)-3-[[[2-(4-(1,1-dimethylethyl)phenyl)-5-ethyl-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876586-79-7 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[(1S,3R)-3-[[[5-(1-methylethyl)-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

AB Title compds. 1 [R = H, CF3; R1 = H, CF3, alkyl, etc.; R2 = H, alkyl, alkoxy, etc.; R3 = alkyl; R4 = alkyl, benzyl; R5 = H, alkyl] and their pharmaceutically acceptable salts were prepared. For example, TFA mediated deprotection of t-Bu ester II (R5 = t-Bu) afforded carboxylic acid II (R5 = H). In PPAR $\gamma$  receptor binding assays, compds. 1 exhibited EC50 values ranging from 0.0016-0.3813  $\mu$ M.


IT 876586-74-2P 876586-75-3P 876586-76-4P  
 876586-77-5P 876586-78-6P 876586-79-7P  
 876586-80-0P 876586-81-1P 876586-82-2P  
 876586-83-3P 876586-85-5P 876586-86-6P  
 876586-88-8P 876586-89-9P 876586-90-2P  
 876586-91-3P 876586-93-5P 876586-94-6P

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of 2-phenyloxazoles as peroxisome proliferator agonist)


RN 876586-74-2 CAPLUS  
 CN Propanoic acid, 2-[[[(1S,3R)-3-[[[5-ethyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876586-75-3 CAPLUS  
 CN Propanoic acid, 2-[[[(1S,3R)-3-[[[5-ethyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876586-76-4 CAPLUS  
 CN Propanoic acid, 2-[[[(1S,3R)-3-[[[5-ethyl-2-(2-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 876586-80-0 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[(1S,3R)-3-[[[5-(1-methylethyl)-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-81-1 CAPLUS  
 CN Propanoic acid, 2-[[[(1S,3R)-3-[[[2-(3,4-dimethylphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-82-2 CAPLUS  
 CN Propanoic acid, 2-[[[(1S,3R)-3-[[[2-(4-(1,1-dimethylethyl)phenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-83-3 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3R)-3-[[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-85-5 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(3,4-dimethylphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-86-6 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(1,1'-biphenyl)-4-yl-5-methyl-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-91-3 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(3-(1,1-dimethylethyl)phenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-93-5 CAPLUS  
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-ethyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-94-6 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(3,4-dimethylphenyl)-5-ethyl-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-88-8 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-89-9 CAPLUS  
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-(1-methylethyl)-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876586-90-2 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(3-(2,2-dimethylpropyl)phenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 876587-02-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of 2-phenyloxazoles as peroxisome proliferator agonist)

RN 876587-02-9 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3R)-3-[[[5-ethyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2006:166904 CAPLUS  
DOCUMENT NUMBER: 144:233062  
TITLE: Preparation of 2-phenylloxazoles as peroxisome proliferator agonist  
INVENTOR(S): Glombik, Heiner; Stapper, Christian; Falk, Eugen; Keil, Stefanie; Schaefer, Hans-Ludwig; Wendler, Wolfgang; Knieps, Stephanie  
PATENT ASSIGNEE(S): Sanofi-Aventis Deutschland G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 73 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018115	A1	20060223	WO 2005-EP8281	20050730
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GM, GG, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>DE 102004039532 A1 20060302 DE 2004-102004039532 20040814 DE 102004039532 B4 20060921 PRIORITY APPLN. INFO.: DE 2004-102004039532A 20040814 OTHER SOURCE(S): MARPAT 144:233062 GI</p>				




L12 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 876588-50-0 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-52-2 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)



RN 876588-53-3 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876588-54-4 CAPLUS  
CN Pentanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)


L12 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

AB Title compds. 1 (R1 = H, alkyl; R2 = H, alkoxy, CF3; R3 = alkyl; R4 = alkyl, benzyl; R5 = H, alkyl) and their pharmaceutically acceptable salts were prepared. For example, TPA mediated deprotection of ester II (R5 = t-Bu) afforded acid I (R5 = H). In PPARγ receptor binding assays, compds. I exhibited EC50 values ranging from 0.00016-0.32μM.

IT 876588-46-4P 876588-47-5P 876588-48-6P  
876588-50-0P 876588-52-2P 876588-53-3P  
876588-54-4P 876588-55-5P 876588-56-6P  
876588-59-9P 876588-60-2P 876588-61-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-phenylloxazoles as peroxisome proliferator agonist)  
RN 876588-46-4 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876588-47-5 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-48-6 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(4-(2,2-dimethylpropyl)phenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

Absolute stereochemistry.




RN 876588-55-5 CAPLUS  
CN Pentanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-56-6 CAPLUS  
CN Pentanoic acid, 2-[[[(1R,3S)-3-[[2-(4-(2,2-dimethylpropyl)phenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-59-9 CAPLUS  
CN Benzenepropanoic acid, α-[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-1-oxo-2-phenylpropanoic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-60-2 CAPLUS  
CN Benzenepropanoic acid,  $\alpha$ -[[(1R,3S)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-61-3 CAPLUS  
CN Benzenepropanoic acid,  $\alpha$ -[[(1R,3S)-3-[[2-[4-(2,2-dimethylpropyl)phenyl]-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 876588-68-0P 876588-74-8P 876588-77-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of 2-phenylloxazoles as peroxisome proliferator agonist)  
RN 876588-68-0 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-74-8 CAPLUS  
CN Pentanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2006:152696 CAPLUS  
DOCUMENT NUMBER: 144:211234  
TITLE: Chemoenzymic process for synthesis of cis-configured 3-hydroxycyclohexane carboxylic acid derivative enantiomers  
INVENTOR(S): Holla, Wolfgang; Keil, Stefanie; Tappertzhofen, Christoph  
PATENT ASSIGNEE(S): Sanofi-Aventis Deutschland GmbH, Germany  
SOURCE: PCT Int. Appl., 77 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006015716	A2	20060216	WO 2005-EP8058	20050723
WO 2006015716	A3	20060622		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004038403	A1	20060223	DE 2004-102004038403	20040807
DE 102004038403	B4	20060831		
PRIORITY APPLN. INFO.: DE 2004-102004038403A 20040807				
OTHER SOURCE(S): MARPAT 144:211234				

AB The invention relates to a method for producing chiral, non-racemic, cis-configured cyclohexanols or cyclohexanol derivs. by means of enzyme catalyzed kinetic resolution of racemates.  
IT 875928-09-9P  
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)  
(chemoenzymic process for synthesis of of cis-configured 3-hydroxycyclohexane carboxylic acid derivative enantiomers)  
RN 875928-09-3 CAPLUS  
CN L-Valine, N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.



RN 876588-77-1 CAPLUS  
CN Benzenepropanoic acid,  $\alpha$ -[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]- $\alpha$ -methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


IT 752213-23-3P 875928-10-2P 875928-11-3P  
875928-24-8P  
RL: FRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)  
(chemoenzymic process for synthesis of of cis-configured 3-hydroxycyclohexane carboxylic acid derivative enantiomers)  
RN 752213-23-3 CAPLUS  
CN L-Valine, N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 875928-10-2 CAPLUS  
CN L-Leucine, N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 875928-11-3 CAPLUS  
CN L-Alanine, N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 875928-24-8 CAPLUS  
CN Cyclohexanecarboxylic acid, 3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]-, (1R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 875928-08-8P 875928-14-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (chemoenzymic process for synthesis of of cis-configured  
 3-hydroxycyclohexane carboxylic acid derivative enantiomers)  
 RN 875928-08-8 CAPLUS  
 CN Cyclohexanecarboxylic acid, 3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]-, 1-methylethyl ester, (1R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875928-14-6 CAPLUS  
 CN D-Valine, N-[[[(1S,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:1262021 CAPLUS

DOCUMENT NUMBER: 144:22913  
 TITLE: Preparation of arylcycloalkyl oxazole derivatives and their use as pharmaceuticals  
 INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schafer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang  
 PATENT ASSIGNER(S): Germany  
 SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 631,867.  
 CODEN: USXXCO  
 Patent  
 DOCUMENT TYPE: English  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005267177	A1	20051201	US 2005-97945	20050404
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
US 2003144332	A1	20030731	US 2002-231432	20020830
US 6624185	B2	20030923		
US 2004122069	A1	20040624	US 2003-631867	20030801
US 6884812	B2	20050426		
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
			DE 2001-10142734	A 20010831
			DE 2002-10223273	A 20020524
			US 2002-231432	A2 20020830
			US 2003-631867	A2 20030801

PRIORITY APPLN. INFO.:  
 OTHER SOURCE(S): MARPAT 144:22913  
 GI




AB The title compds. I [ring A = (C3-C8)-cycloalkyl; R1, R2, R4, R5 = H, F, Cl, Br, OH, NO2, cyano, CF3, OCF3, (C1-C6)-alkyl, O(C1-C6)-alkyl; R3 = H, (C1-C6)-alkyl; X, Y = (C1-C2)-alkyl where one C atom is replaced by O] and their physiol. acceptable salts and physiol. functional derivs. are disclosed. For example, reacting cyclopent-2-ene-1,4-diol with Me 2-(bromomethyl)-6-methylbenzoate followed by hydrolysis of the ester gave

L12 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

benzoic acid II. The compds. typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metab., of type II diabetes, and of syndrome X.


IT 501362-35-2P 501362-38-5P 501362-39-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)  
 RN 501362-35-2 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-38-5 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-39-6 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 501362-33-0P 501362-36-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)  
 RN 501362-33-0 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

L12 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 501362-36-3 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



INVENTOR(S): Gratzke, Dirk; Glombik, Heiner; Falk, Eugen; Goerlitz, Jochen; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: PCT Int. Appl., 119 pp.  
 CODEN: PIXXD2  
 Patent

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076447	A1	20040910	WO 2004-EP1585	20040219
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TH, TJ, TM, TR, TT, TZ, UA, UG, UZ, VC, VE, VN, YU, ZA, ZM, ZW, AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CU, CV, CW, CX, CY, CZ, DA, DB, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UU, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.				
DE 10308354	A1	20041223	DE 2003-10308354	20030227
AU 2004215676	A1	20040910	AU 2004-215676	20040219
CA 2516657	A1	20040910	CA 2004-2516657	20040219
EP 1601671	A1	20051207	EP 2004-712484	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, ER, HU, SK				
BR 2004007867	A	20060301	BR 2004-7867	20040219
CN 1753887	A	20060329	CN 2004-80005449	20040219
JP 200619198	T	20060824	JP 2006-501891	20040219
US 2004198786	A1	20041007	US 2004-789865	20040227
US 7148246	B2	20051212		
NO 2005004397	A	20051123	NO 2005-4397	20050922
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): MARPAT 141:260738				
GI				

(Uses)

(prepn. of oxazolylmethoxycyclohexanols as PPAR $\alpha$  agonists for the treatment of type II diabetes)


RN 755419-15-9 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazoly]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 755419-93-3P 755419-98-8P 755420-03-2P  
 755420-08-7P 755420-15-6P 755420-21-4P  
 RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of oxazolylmethoxycyclohexanols as PPAR $\alpha$  agonists for the treatment of type II diabetes)  
 RN 755419-93-3 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazoly]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755419-98-8 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazoly]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-03-2 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-(4-(1-methylethyl)phenyl)-4-oxazoly]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)




AB Title compds. I [R = (un)substituted Ph, annulated Ph; R1 = H, CF<sub>3</sub>, alkyl, alkoxy, cycloalkyl, Ph; R2 = (un)substituted Ph, oxoheterocyclyl; X = alkanediyl, oxoalkenediyl; X1 = cycloalkenediyl, cycloalkenediyl, oxocycloalkenediyl, oxocycloalkenediyl; Y = (un)substituted alkanediyl, alkenediyl] were prepared for treating and/or preventing disturbances of fatty acid metabolism, impaired glucose utilization, and disturbances in

which insulin resistance plays a role. Thus, 2-(4-fluorophenyl)-4-iodomethyl-5-methylthiazole was treated with 1,3-cyclohexanediol, followed by 3-OZNC6H<sub>4</sub>CH<sub>2</sub>Br to give the title compound II which had EC<sub>50</sub> for activation of the PPAR $\alpha$  receptor of 91 nM. Compds. I are claimed useful for the treatment of type II diabetes.

IT 755419-21-7P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RAGT (Reactant or reagent); USES (Uses)  
 (preparation of oxazolylmethoxycyclohexanols as PPAR $\alpha$  agonists for the treatment of type II diabetes)

RN 755419-21-7 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazoly]methoxy]cyclohexyl]methylene]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
 Double bond geometry unknown.



IT 755419-15-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(methylthyl)phenyl]-4-oxazoly]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-08-7 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-ethyl-2-(4-(1-methylethyl)phenyl)-4-oxazoly]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755420-15-6 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazoly]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755420-21-4 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazoly]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






IT 754987-06-9 755421-77-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of oxazolyimethoxycyclohexanols as PPAR $\alpha$  agonists for the treatment of type II diabetes)  
 RN 754987-06-9 CAPLUS  
 CN Cyclohexanecetaldehyde, 3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazoly]methoxy]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755421-77-3 CAPLUS  
 CN Cyclohexanecetaldehyde, 3-[[5-methyl-2-(4-methylphenyl)-4-oxazoly]methoxy]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 753459-84-6P 753459-85-7P 754986-70-4P  
 755421-65-9P 755421-83-1P 755422-77-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of oxazolyimethoxycyclohexanols as PPAR $\alpha$  agonists for the treatment of type II diabetes)  
 RN 753459-84-6 CAPLUS  
 CN Oxazole, 4-[[[(1R,3S)-3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]cyclohexyl]oxy]methyl]-5-methyl-2-(4-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L12 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 oxazoly]methoxycyclohexyl]ethylidene]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
 Double bond geometry unknown.




RN 755422-77-6 CAPLUS  
 CN Cyclohexanecetaldehyde, 3-[[5-methyl-2-(3-methylphenyl)-4-oxazoly]methoxy]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 755418-86-1P 755418-92-9P 755418-98-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of oxazolyimethoxycyclohexanols as PPAR $\alpha$  agonists for the treatment of type II diabetes)  
 RN 755418-86-1 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[1-hydroxy-2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazoly]methoxycyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 755418-92-9 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[1-hydroxy-2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazoly]methoxycyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L12 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 753459-85-7 CAPLUS  
 CN Cyclohexanemethanol, 3-[[5-methyl-2-(4-methylphenyl)-4-oxazoly]methoxy]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-70-4 CAPLUS  
 CN Cyclohexanecarboxaldehyde, 3-[[5-methyl-2-(4-methylphenyl)-4-oxazoly]methoxy]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755421-65-9 CAPLUS  
 CN Oxazole, 5-methyl-2-(3-methylphenyl)-4-[[[(1R,3R)-3-(2-propenyl)cyclohexyl]oxy]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755421-83-1 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-

L12 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 755418-98-5 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[1-hydroxy-2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazoly]methoxycyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 755419-05-7P 755419-10-4P 755419-27-3P  
 755419-33-1P 755419-38-6P 755419-43-3P  
 755419-49-9P 755419-54-6P 755419-61-5P  
 755419-65-9P 755419-71-7P 755419-76-2P  
 755419-80-8P 755419-87-5P 755420-26-9P  
 755420-33-8P 755420-42-9P 755420-48-5P  
 755420-52-1P 755420-57-6P 755420-63-4P  
 755420-67-8P 755420-73-6P 755420-79-2P  
 755420-87-2P 755420-93-0P 755420-98-5P  
 755421-04-6P 755421-09-1P 755421-15-9P  
 755421-22-8P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of oxazolyimethoxycyclohexanols as PPAR $\alpha$  agonists for the treatment of type II diabetes)  
 RN 755419-05-7 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazoly]methoxycyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755419-10-4 CAPLUS  
 CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-

Relative stereochemistry.




RN 755419-27-3 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755419-33-1 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-cyclohexyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755419-38-6 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-cyclohexyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755419-61-5 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 755419-65-9 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-ethyl-2-(2-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755419-71-7 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755419-43-3 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[2-(3,5-bis(trifluoromethyl)phenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755419-49-9 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[2-(2,6-dimethylphenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755419-54-6 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-methyl-2-(2-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


RN 755419-76-2 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-ethyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755419-80-8 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-(1-methylethyl)-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755419-87-5 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1R,3R)-3-[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755420-26-9 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[[[(1S,3S)-3-[[2-(3,4-dimethylphenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-33-8 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-42-9 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-48-5 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-(4-(1,1-dimethylethyl)phenyl)-5-ethyl-4-oxazolyl)methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-67-8 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-(4-(1,1-dimethylethyl)phenyl)-5-(1-methylethyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-73-6 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-(1-methylethyl)-2-(4-(2-methylpropyl)phenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-79-2 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-(1-methylethyl)-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-52-1 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[2-(3,4-dimethylphenyl)-5-(1-methylethyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-57-6 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-ethyl-2-(4-(2-methylpropyl)phenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-63-4 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1S,3S)-3-[[5-(1-methylethyl)-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755420-87-2 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]ethyl]-3-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755420-93-0 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]ethyl]-3-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755420-98-5 CAPLUS  
CN 2,4-Thiazolidinedione, 3-methyl-5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L12 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 755421-04-6 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-3-(phenylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755421-09-1 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-(1-methyl-4-oxazolyl)methoxy]cyclohexyl]ethyl]-3-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755421-15-9 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]-3-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755421-22-8 CAPLUS  
CN 2,4-Thiazolidinedione, 5-[2-[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]ethyl]-3-phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:740307 CAPLUS  
DOCUMENT NUMBER: 141:260736  
TITLE: Preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid derivatives and related compounds used as PPAR modulators for treating type 2 diabetes and arteriosclerosis  
INVENTOR(S): Stapper, Christian; Gretzke, Dirk; Glombik, Helmut; Falk, Eugen; Goerlitzer, Jochen; Keil, Stefanie; Schaefer, Hans-Ludwig; Wendler, Wolfgang  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
SOURCE: FCT Int. Appl., 189 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076427	A1	20040910	WO 2004-EP1579	20040219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, PY, RE, RO, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VU, WO, WS, XG, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, NI, NG, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, PY, RE, RO, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VU, WO, WS, XG, YU, ZA, ZM, ZW			
DE 10308355	A1	20041223	DE 2003-10308355	20030227
AU 2004215673	A1	20040910	AU 2004-215673	20040219
CA 2517381	A1	20040910	CA 2004-2517381	20040219
EP 1599452	A1	20051130	EP 2004-712490	20040219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007758	A	20060214	BR 2004-7758	20040219
CN 1753879	A	20060329	CN 2004-80005437	20040219
CN 1753881	A	20060329	CN 2004-80005476	20040219
CN 1756748	A	20060405	CN 2004-80005498	20040219
JP 2006519194	T	20060824	JP 2006-501886	20040219
US 2004209920	A1	20041021	US 2004-789017	20040227
US 2005101637	A1	20050512	US 2004-788996	20040227
US 2005215596	A1	20050929	US 2004-788997	20040227
ZA 2005005768	A	20051123	ZA 2005-5768	20050719
NO 2005004408	A	20051123	NO 2005-4408	20050922
PRIORITY APPL. INFO.:			DE 2003-10308355	A 20030227
			US 2003-487510P	P 20030715
			WO 2004-EP1579	A 20040219


OTHER SOURCE(S): MARPAT 141:260736  
GI

L12 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [X = alkanediyl, oxalkanediyl; X1 = cycloalkanediyl, cycloalkenediyl, oxacycloalkanediyl, oxacycloalkenediyl; Y1 = (un)substituted CH2, CH2CH2; Y2 = CH2, O, S, S(O), SO2, (un)substituted NH; R = (un)substituted or annulated Ph, pyridinyl, furyl, thienyl, pyrrolyl; R1 = H, alkyl, cycloalkyl, cycloalkylalkyl, Ph, aralkyl, heteroaryl, heteroarylalkyl, fluoroalkyl; R2, R3 = H, alkyl, F, (un)substituted NH; R4 = H, alkyl, F; R5 = H, F, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, Ph, substituted alkyl; CR4R5 = cycloalkyl; R6 = H, alkyl] were prepared for use as PPAR modulators for treating disorders of the fatty acid metabolism and disorders of glucose utilization in addition to disorders, in which insulin resistance plays a part. Thus, the title compound II was prepared in a multi-stage synthesis and had EC50 for activation of the PPAR $\alpha$  receptor of 0.07 nM.

IT 754986-49-7P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid  
derivs. and related compds. as PPAR agonists)  
RN 754986-49-7 CAPLUS  
CN Acetic acid, [[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 754986-13-5P 754986-20-4P 754986-25-9P  
754986-36-2P 754986-51-1P 754986-61-3P  
754986-66-8P 754986-72-6P 754986-83-9P  
754987-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic

acid  
derivs. and related compds. as PPAR agonists)

RN 754986-13-5 CAPLUS

CN Benzenepropanoic acid, α-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-20-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754986-25-9 CAPLUS


CN Cyclopentanecarboxylic acid, 1-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 754986-66-8 CAPLUS

CN Heptanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]sulfonyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-72-6 CAPLUS

CN L-Valine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 754986-83-9 CAPLUS

CN L-Valine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 754987-21-8 CAPLUS

CN Cyclohexanecarboxylic acid, 3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-36-2 CAPLUS

CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-51-1 CAPLUS

CN Butanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]thio]-, rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RN 754986-61-3 CAPLUS

CN Heptanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]sulfinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 753459-85-7P 753459-87-9P 754986-09-9P

754986-18-0P 754986-24-8P 754986-29-3P

754986-46-4P 754986-48-6P 754986-70-4P

754986-71-5P 754986-86-2P 754987-05-8P

754987-06-9P 754987-07-0P 754987-08-1P

754987-11-6P 754987-14-9P 754987-24-1P

754987-30-9P 754987-31-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic

acid  
derivs. and related compds. as PPAR agonists)

RN 753459-85-7 CAPLUS

CN Cyclohexanemethanol, 3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 753459-87-9 CAPLUS


CN Oxazole, 4-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-5-methyl-2-(4-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-09-9 CAPLUS

CN Pentanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)




RN 754986-18-0 CAPLUS  
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-24-8 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-29-3 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


RN 754986-71-5 CAPLUS  
CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 754986-86-2 CAPLUS  
CN Glycine, N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-N-(2-chienylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-05-8 CAPLUS  
CN Oxazole, 2-(3-methoxyphenyl)-5-methyl-4-[[[(1R,3R)-3-(2-propenyl)cyclohexyl]oxy]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-06-9 CAPLUS  
CN Cyclohexanecarboxaldehyde, 3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-46-4 CAPLUS  
CN Cyclohexanecarboxylic acid, 3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]-, methyl ester, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 754986-48-6 CAPLUS  
CN Acetic acid, [[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-70-4 CAPLUS  
CN Cyclohexanecarboxaldehyde, 3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-07-0 CAPLUS  
CN 2-Butenoic acid, 4-[[[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry unknown.




RN 754987-08-1 CAPLUS  
CN Cyclohexanecarboxaldehyde, 3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, ethyl ester, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-11-6 CAPLUS  
CN 2-Butenoic acid, 2-ethyl-4-[[[(1R,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry unknown.




RN 754987-14-9 CAPLUS  
 CN Cyclohexanecarboxylic acid,  $\alpha,\alpha$ -dimethyl-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]-, 1,1-dimethylethyl ester, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-24-1 CAPLUS  
 CN Cyclohexanecarboxylic acid, 3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]- $\alpha$ -(2-methyl-2-propenyl)-, 1,1-dimethylethyl ester, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754987-30-9 CAPLUS  
 CN L-Valine, N-[2-[[3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 754987-31-0 CAPLUS  
 CN L-Valine, N-[4-(4-methoxyphenoxy)carbonyl]-N-[2-[[3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Relative stereochemistry.



RN 754986-57-7 CAPLUS  
 CN Pentanoic acid, 2-[[[1R,3S]-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 754986-10-2P 754986-11-3P 754986-12-4P  
 754986-14-6P 754986-15-7P 754986-16-8P  
 754986-19-1P 754986-30-6P 754986-31-7P  
 754986-32-8P 754986-34-0P 754986-35-1P  
 754986-37-3P 754986-39-5P 754986-40-8P  
 754986-41-9P 754986-50-0P 754986-55-5P  
 754986-56-6P 754986-58-8P 754986-60-2P  
 754986-62-4P 754986-63-5P 754986-64-6P  
 754986-65-7P 754986-67-9P 754986-68-0P  
 754986-69-1P 754986-73-7P 754986-74-8P  
 754986-75-9P 754986-76-0P 754986-77-1P  
 754986-78-2P 754986-80-6P 754986-82-8P  
 754986-85-1P 754986-87-3P 754986-92-0P  
 754986-93-1P 754986-95-3P 754986-96-4P  
 754986-98-6P 754986-99-7P 754987-00-3P  
 754987-01-4P 754987-03-6P 754987-04-7P  
 754987-05-2P 754987-10-5P 754987-12-7P  
 754987-13-6P 754987-15-0P 754987-16-1P  
 754987-20-7P 754987-23-0P 754987-25-2P  
 754987-27-4P 754987-29-6P 754987-32-1P  
 754987-33-2P 754987-34-3P 754987-35-4P  
 754987-36-5P 754987-37-6P 754987-38-7P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid derivs. and related compds. as PPAR agonists)

RN 754986-10-2 CAPLUS  
 CN Pentanoic acid, 2-[[[1R,3S]-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 754986-52-2P 754986-53-3P 754986-54-4P  
 754986-57-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid derivs. and related compds. as PPAR agonists)


RN 754986-52-2 CAPLUS  
 CN Heptanoic acid, 2-[[[1R,3S]-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-53-3 CAPLUS  
 CN Butanoic acid, 3-methyl-2-[[[1R,3S]-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-54-4 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[1R,3S]-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)




RN 754986-11-3 CAPLUS  
 CN Propanoic acid, 2-[[[1R,3S]-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-12-4 CAPLUS  
 CN Butanoic acid, 2-[[[1R,3S]-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-14-6 CAPLUS  
 CN Propanoic acid, 2-[[[1R,3S]-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-15-7 CAPLUS


L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-16-8 CAPLUS  
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-19-1 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-30-6 CAPLUS  
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 754986-35-1 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[2-(4-methylphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-37-3 CAPLUS  
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-39-5 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(3-(trifluoromethoxy)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 754986-31-7 CAPLUS  
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754986-32-8 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-34-0 CAPLUS  
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 754986-40-8 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-41-9 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-50-0 CAPLUS  
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 754986-55-5 CAPLUS  
CN Benzenecetic acid,  $\alpha$ -[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-56-6 CAPLUS  
CN Cyclohexanecarboxylic acid,  $\alpha$ -[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-58-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-60-2 CAPLUS  
CN Acetic acid, [[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Acetic acid, [[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-67-9 CAPLUS  
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-68-0 CAPLUS  
CN Butanoic acid, 3-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-69-1 CAPLUS  
CN Pentanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 754986-62-4 CAPLUS  
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-63-5 CAPLUS  
CN Butanoic acid, 3-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-64-6 CAPLUS  
CN Pentanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-65-7 CAPLUS

L12 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 754986-73-7 CAPLUS  
CN L-Valine, N-acetyl-N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 754986-74-8 CAPLUS  
CN L-Valine, N-benzoyl-N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 754986-75-9 CAPLUS  
CN L-Valine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 754986-76-0 CAPLUS  
 CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-[(methylsulfonyl)methyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 754986-77-1 CAPLUS  
 CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754986-78-2 CAPLUS  
 CN L-Valine, N-(methoxycarbonyl)-N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754986-80-6 CAPLUS  
 CN Glycine, N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)




RN 754986-85-1 CAPLUS  
 CN Glycine, N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-(phenylmethyl)-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 754986-84-0  
 CHF C28 H34 N2 O4

Relative stereochemistry.



CH 2

CRN 76-05-1  
 CHF C2 H F3 O2




RN 754986-87-3 CAPLUS  
 CN Glycine, N-(cyclohexylmethyl)-N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

CH 1

CRN 754986-79-3  
 CHF C21 H28 N2 O4

Relative stereochemistry.



CH 2

CRN 76-05-1  
 CHF C2 H F3 O2




RN 754986-82-8 CAPLUS  
 CN L-Valine, N-methyl-N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 754986-81-7  
 CHF C25 H36 N2 O4

Absolute stereochemistry.




CH 2

CRN 76-05-1  
 CHF C2 H F3 O2




RN 754986-92-0 CAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-93-1 CAPLUS  
 CN Butanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-95-3 CAPLUS  
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-[[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-96-4 CAPLUS  
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-phenyl-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-98-6 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-99-7 CAPLUS  
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-00-3 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-cyclohexyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-01-4 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-03-6 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-04-7 CAPLUS  
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(4-methyl-3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-09-2 CAPLUS  
CN Cyclohexanebutanoic acid, 3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-10-5 CAPLUS  
CN Cyclohexanebutanoic acid, 3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-12-7 CAPLUS  
CN Cyclohexanebutanoic acid, 3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-13-8 CAPLUS  
CN Cyclohexanebutanoic acid, 3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-15-0 CAPLUS  
CN Cyclohexanebutanoic acid, 3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-16-1 CAPLUS  
CN Cyclohexanebutanoic acid, 3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-20-7 CAPLUS  
CN Cyclohexanebutanoic acid, 3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-23-0 CAPLUS  
CN Benzenepropanoic acid, α-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-25-2 CAPLUS  
CN Cyclohexanebutanoic acid, 3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]-α-(2-methylpropyl)-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-27-4 CAPLUS  
CN Cyclohexanebutanoic acid, 3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-α,α-dipropyl-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-29-6 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[2-[(1R,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-32-1 CAPLUS  
CN L-Valine, N-[(4-methoxyphenyl)carbonyl]-N-[2-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 754987-33-2 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl][(phenylmethoxy)carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-34-3 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[(4-methoxyphenyl)methoxy]carbonyl][2-[[1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754987-35-4 CAPLUS  
CN D-Phenylalanine, N-[[[(4-methoxyphenyl)methoxy]carbonyl]-α-methyl-N-[2-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

Me


RN 754987-36-5 CAPLUS  
CN Glycine, N-[2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-N-[(phenylmethoxy)carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-37-6 CAPLUS  
CN Glycine, N-[2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-N-(phenylacetyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754987-38-7 CAPLUS  
CN Glycine, N-[2-[(1R,3R)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-N-[(phenylamino)carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2004:740306 CAPLUS

DOCUMENT NUMBER: 141:243829

TITLE: Synthesis of oxazol-4-yl-cyclohexanecarbonyl-amino acid derivatives as peroxisome proliferator activated receptor (ppar) modulators for the treatment of type 2 diabetes and atherosclerosis

INVENTOR(S): Stapper, Christian; Gretzke, Dirk; Falk, Eugen; Goerlitz, Jochen; Keil, Stefanie; Schaefer, Hans-Ludwig; Glombik, Heiner; Wendler, Wolfgang

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076426	A1	20040910	WO 2004-EP1578	20040219
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RW, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VU, WO, XA, XB, XC, XE, XG, XI, XJ, XK, XL, XM, XN, XP, XQ, XR, XS, XT, XU, XW, XX, YY, YZ			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, HR, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RW, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VU, WO, XA, XB, XC, XE, XG, XI, XJ, XK, XL, XM, XN, XP, XQ, XR, XS, XT, XU, XW, XX, YY, YZ			
DE 10308355	A1	20041223	DE 2003-10308355	20030227
AU 2004215672	A1	20040910	AU 2004-215672	20040219
CA 2516620	A1	20040910	CA 2004-2516620	20040219
EP 1599453	A1	20051130	EP 2004-712494	20040219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007814	A	20060214	BR 2004-7814	20040219
CN 1753879	A	20060329	CN 2004-80005437	20040219
CN 1753881	A	20060329	CN 2004-80005476	20040219
CN 1756748	A	20060405	CN 2004-80005498	20040219
JP 2006519193	T	20060824	JP 2006-501885	20040219
US 2004209920	A1	20041021	US 2004-789017	20040227
US 2005101637	A1	20050512	US 2004-788996	20040227
US 2005215596	A1	20050929	US 2004-788997	20040227
ZA 2005005768	A	20051123	ZA 2005-5768	20050719
NO 2005004396	A	20051111	NO 2005-4396	20050922
PRIORITY APPL. INFO.:			DE 2003-10308355	A 20030227
			WO 2004-EP1578	A 20040219

OTHER SOURCE(S): MARPAT 141:243829

GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to cis-cyclohexyl-substituted amino acid deriva., e.g. (I), and their physiol. acceptable salts and physiol. functional deriva., as suitable compds. for treatment and/or prevention of disturbances of fatty acid metabolism, impaired glucose utilization, and disturbances in which insulin resistance plays a role, for example.

L12 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


RN 752213-30-2 CAPLUS  
CN Alanine, 2-methyl-N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752213-41-5 CAPLUS  
CN L-Valine, N-[[[3-[[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752213-69-7 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 752214-13-4 CAPLUS  
CN L-Valine, N-[[[3-[[[5-(1-methylethyl)-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

Intermediate (II) was prepd. from Et 4-methyl-3-oxo-pentanoic acid, which was reacted with sodium nitrite in water to give Et 2-hydroxyimino-4-methyl-3-oxo-pentanoic acid, which was then reduced to the amine hydrochloride salt, reacted with 4-methylbenzoyl chloride, and the product cyclized to the substituted oxazole using phosphoroxylchloride. The resulting intermediate was reduced to the 4-methanol deriv., which was iodinated to give II. Intermediate (III) was prepd. from 6-oxabicyclo[3.2.1]octan-7-one by formation of the ring-opened Me ester diphenyl-methylsilyl ether deriv., which was coupled with H-L-Val-OtBu, and the product O-deprotected. Coupling of II and III gave title compds. Sepn. of the cis-cyclohexane isomers could be accomplished using HPLC techniques. Title compd. (IV), prepd. in the same fashion using H-L-Ala-OtBu and III prepd. from 3-oxabicyclo[3.3.1]nonane, had EC50 of 1.2 nM when tested in vitro against PPAR $\alpha$ ; similarly prepd. I had EC50 99 nM.

IT 752213-61-9P  
RL: BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)

RN 752213-61-9 CAPLUS  
CN L-Valine, N-[[[3-[[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 752213-28-8P 752213-30-2P 752213-41-5P  
752213-69-7P 752214-13-4P 752214-14-5P  
752214-21-4P  
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)

RN 752213-28-8 CAPLUS  
CN L-Alanine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


RN 752214-14-5 CAPLUS  
CN L-Valine, N-[[[3-[[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752214-21-4 CAPLUS  
CN L-Valine, N-[[[3-[[[5-ethyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 752213-21-1P 752213-59-5P  
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
(preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)

RN 752213-21-1 CAPLUS  
CN L-Valine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 752213-59-5 CAPLUS  
CN L-Valine, N-[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 752213-23-3P 752213-25-5P  
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)

RN 752213-23-3 CAPLUS  
CN L-Valine, N-[[1R,3S]-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-25-5 CAPLUS  
CN L-Valine, N-[[1S,3R]-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

752213-83-5P 752213-87-9P 752213-88-0P  
752213-89-1P 752213-92-6P 752213-95-9P  
752213-98-2P 752214-01-0P 752214-07-6P  
752214-08-7P 752214-09-8P 752214-10-1P  
752214-11-2P 752214-15-6P 752214-16-7P  
752214-17-8P 752214-18-9P 752214-20-3P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)


RN 752213-26-6 CAPLUS  
CN L-Leucine, N-[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-29-9 CAPLUS  
CN L-Phenylalanine, N-[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-32-4 CAPLUS  
CN D-Valine, N-[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-34-6 CAPLUS  
CN L-Proline, 1-[[3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 752213-06-2P 752213-20-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)


RN 752213-06-2 CAPLUS  
CN Cyclohexanecarboxylic acid, 1-[[[1R,3S]-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752213-20-0 CAPLUS  
CN L-Valine, N-[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 752213-26-6P 752213-29-9P 752213-32-4P  
752213-34-6P 752213-36-8P 752213-38-0P  
752213-40-4P 752213-43-7P 752213-45-9P  
752213-47-1P 752213-49-3P 752213-51-7P  
752213-53-9P 752213-55-1P 752213-57-3P  
752213-63-1P 752213-65-3P 752213-67-5P  
752213-71-1P 752213-75-5P 752213-79-9P

Absolute stereochemistry.




RN 752213-36-8 CAPLUS  
CN L-Proline, 1-[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-38-0 CAPLUS  
CN L-Valine, N-[[3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-40-4 CAPLUS  
CN L-Valine, N-[[3-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-43-7 CAPLUS  
CN L-Valine, N-[[3-[[5-(1-methylethyl)-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-45-9 CAPLUS  
CN L-Valine, N-[[3-[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-47-1 CAPLUS  
CN L-Valine, N-[[3-[[2-(3-methoxyphenyl)-5-(trifluoromethyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-49-3 CAPLUS




RN 752213-57-3 CAPLUS  
CN L-Valine, N-[[3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752213-63-1 CAPLUS  
CN L-Valine, N-[[3-[[5-cyclohexyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-65-3 CAPLUS  
CN L-Valine, N-[[3-[[5-cyclohexyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN L-Valine, N-[[3-[[5-(trifluoromethyl)-2-[[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-51-7 CAPLUS  
CN L-Valine, N-[[3-[[2-(4-methylphenyl)-5-(trifluoromethyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-53-9 CAPLUS  
CN L-Valine, N-[[3-[[2-(4-methylphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-55-1 CAPLUS  
CN L-Valine, N-[[3-[[2-(3-methoxyphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-67-5 CAPLUS  
CN Cyclohexanecarboxylic acid, 1-[[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752213-71-1 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752213-75-5 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[5-methyl-2-[[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752213-79-9 CAPLUS  
CN L-Valine, N-methyl-N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-83-5 CAPLUS  
CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-87-9 CAPLUS  
CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Relative stereochemistry.




RN 752213-98-2 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[2-(3,4-dimethylphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 752214-01-0 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752214-07-6 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


RN 752213-89-0 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752213-89-1 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[2-(3,5-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752213-92-6 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[5-(1-methylethyl)-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752213-95-9 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[5-ethyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752214-08-7 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[5-methyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 752214-09-8 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[[[(1R,3S)-3-[[5-ethyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 752214-10-1 CAPLUS  
CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







Absolute stereochemistry.



**Absolute stereochemistry.**



### Absolute stereochemistry




L12 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:740160 CAPLUS  
DOCUMENT NUMBER: 141:260735  
TITLE: Production method for 1,3-substituted cycloalkyl derivatives containing acidic, mainly heterocyclic groups and use thereof as medicaments  
INVENTOR(S): Goerlitzer, Jochen; Glombik, Hainer; Falk, Eugen; Gretzke, Dirk; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 108 pp.  
DOCUMENT TYPE: CODEN: PIXXD2  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: German 2  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075891	A1	20040910	200404-EP1582	200402019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GN, GU, HW, HU, IL, IN, JP, KE, KG, KH, KR, KW, KZ, LA, LI, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RE, RO, RU, SD, SE, SI, SK, ST, SV, SY, TC, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VN, YU, ZA, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, CA, GN, GQ, GW, HT, HR, NE, SN, TG				
DE 10308315	A1	200401125	200301038351	200303027
AU 2004216519	A1	20040910	AU 2004-216519	200402019
CA 2517307	A1	20040910	CA 2004-2517307	200402019
EP 1599203	A1	200501130	EP 2004-712489	200402019
IR: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MK, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007869	A	20060301	BR 2004-7869	200402019
CN 1753671	A	20060329	CN 2004-80005448	200402019
JP 2006519195	T	20060824	JP 2006-501888	200402019
US 2004209932	A1	200401201	US 2004-789281	200402027
PRIORITY APPLM. INFO.:			US 2003-730361	200303227
			US 2003-487566P	200307015
			WO 2004-EP1582	A 200402019

OTHER SOURCE(S): MARPAT 141:260735  
GI


RN 752214-17-8 CAPLUS  
 CN L-Valine, N-[[3-[[[5-cyclohexyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy)methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.



Absolute stereochemistry.





Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



**AB** The invention relates to 1,3-substituted cycloalkyl derivs. containing acidic, mainly heterocyclic groups, in addition to their physiol. compatible salts and physiол. functional derivs. The invention relates to compds. I [A = C3-8-cycloalkanediyl, C3-8-cycloalkenediyl] optionally containing an O instead of one C; E = (CH<sub>2</sub>)<sub>m</sub>; R<sub>1</sub>, R<sub>2</sub> = H, F, Br, Cl, SF<sub>5</sub>, S-(C1-6-alkyl), CF<sub>3</sub>, OCF<sub>3</sub>, C1-6-alkyl, O-(C1-6-alkoxy), C(C1-6-alkyl)1-3, CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>OPh, R<sub>3</sub> = H, CF<sub>3</sub>, C1-6-alkyl, C3-8-cycloalkyl, Ph; X = C1-6-alkanediy, optionally containing an O instead of C; Y = S, O, bond; m = 1 - 3; n = 0, 1; Z = O, S, C=O, C(=O)NH; R = H, OH, CH<sub>2</sub>CONHOH, CH<sub>2</sub>CONH(C1-6-alkyl), CH<sub>2</sub>CONH(C1-6-alkoxy), NR<sub>4</sub>R<sub>5</sub>, 5- to 12-membered mono- or bicyclic, (un)saturated ring containing 1 or more N, O, S; R<sub>4</sub> = H, C1-6-alkyl] optionally substituted with F, Cl, Br, CN, SH, CO<sub>2</sub>H, C1-4-alkyl, C1-6-alkoxy, SO<sub>2</sub>(C1-4-alkyl), NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, C1-6-alkyl], C1-6-alkoxy], C1-6-alkoxy)-(C1-6-alkoxy)-(C1-6-alkoxy)-C1-6-alkoxy]CG<sub>6</sub>H, OPh, NHSO<sub>2</sub>CF<sub>3</sub>, B(OH)<sub>2</sub>; R<sub>5</sub> = OH, NH<sub>2</sub>, SO<sub>2</sub>CF<sub>3</sub>, SO<sub>2</sub>CG<sub>6</sub>H4CF<sub>3</sub>, COCF<sub>3</sub>, C1-6-alkoxy, Ph, CG<sub>6</sub>H<sub>4</sub>Me, CG<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H; NR<sub>4</sub>R<sub>5</sub> = (un)substituted 5-membered aromatic heterocycle, optionally fused with 5- to 7-membered aromatic heterocycle [optionally substituted with F, Cl, Br, CF<sub>3</sub>, OCF<sub>3</sub>, CO<sub>2</sub>H, SO<sub>2</sub>Me, CN, C1-4-alkoxy, C1-4-alkyl, C1-4-alkyl]CG<sub>6</sub>H, C1-6-alkyl], C1-6-alkoxy], C1-6-alkoxy)-(C1-6-alkoxy), C1-6-alkoxy]-[C1-6-alkoxy]CG<sub>6</sub>H, OPh]], in addition to their physiol. compatible salts and to a method for their production.


IT	disorders, in which insulin resistance plays a part. 753459-87-9
RL:	ROCT (Reactant); RACT (Reactant or reagent) ( $\alpha$ -allylation by, of hydroxythiophenecarboxylate derivs.; preparation of 1,3-substituted cycloalkane heterocyclic derivs. for use in treating metabolic disorders)
RN	753459-87-9 CAPLUS
CN	Oxazole, 4-[[[(1R,3S)-3-(iodomethyl)cyclohexyl]oxylmethyl]-5-methyl-2-(4-

Relative stereochemistry.




IT 753459-84-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and desilylation of; preparation of 1,3-substituted cycloalkane heterocyclic derivs. for use in treating metabolic disorders)  
RN 753459-84-6 CAPLUS  
CN Oxazole, 4-[[[(1R,3S)-3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]cyclohexyl]methoxy]methyl]-5-methyl-2-(4-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 753459-86-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and nucleophilic substitution reactions of; preparation of 1,3-substituted cycloalkane heterocyclic derivs. for use in treating metabolic disorders)  
RN 753459-86-8 CAPLUS  
CN Cyclohexanemethanol, 3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]-, 4-methylbenzenesulfonate (ester), (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 753459-88-0P




RN 753459-54-0 CAPLUS  
CN 1H-Pyrrole-2-carboxylic acid, 1-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 753459-55-1 CAPLUS  
CN 1H-Pyrrole-2-carboxylic acid, 1-[[[(1R,3S)-3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 753459-56-2 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 753459-57-3 CAPLUS


L12 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and sapon. of; prepn. of 1,3-substituted cycloalkane heterocyclic derivs. for use in treating metabolic disorders)  
RN 753459-88-0 CAPLUS  
CN 2-Thiophenecarboxylic acid, 3-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 753459-85-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and tosylation of; preparation of 1,3-substituted cycloalkane heterocyclic derivs. for use in treating metabolic disorders)  
RN 753459-85-7 CAPLUS  
CN Cyclohexanemethanol, 3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]-, (1R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 753459-53-9P 753459-54-0P 753459-55-1P  
753459-56-2P 753459-57-3P 753459-58-4P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 1,3-substituted cycloalkane heterocyclic derivs. for use in treating metabolic disorders)

RN 753459-53-9 CAPLUS  
CN 1H-Indole-2-carboxylic acid, 1-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L12 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
CN 2-Thiophenecarboxylic acid, 3-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-5-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 753459-58-4 CAPLUS  
CN Benzo[b]thiophene-2-carboxylic acid, 6-chloro-3-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:513338 CAPLUS  
 DOCUMENT NUMBER: 141:71532  
 TITLE: Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators  
 INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schaefer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 231,432.  
 CODEN: USXXCO  
 Patent  
 DOCUMENT TYPE: English  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004122069	A1	20040624	US 2003-631867	20030801
US 6884812	B2	20050426		
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
US 2003144332	A1	20030731	US 2002-231432	20020830
US 6624185	B2	20030923		
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
US 2005267177	A1	20051201	US 2005-97345	20050404
			DE 2001-10142734	A 20010831
			DE 2002-10223273	A 20020524
			US 2002-231432	A2 20020830
			US 2003-631867	A2 20030801

OTHER SOURCE(S): MARPAT 141:71532  
 GI




AB Title oxazoles I [2 = cycloalkyl; R1, R2, R4, R5 = H, F, Cl, Br, etc.; R3

L12 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 501362-38-5 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-39-6 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 = H, Me; X, Y = alkyl (chains may contain 1 or more oxygens)] are prepd. Thus, (+)-cis-oxazole II was prepd. from cyclohexane-1,3-diol via O-alkylation with 4-(iodomethyl)-2-(4-fluorophenyl)oxazole, sepn. of cis/trans isomers, HPLC resolu. of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was detd. [EC50 = 0.3 nM vs. PPARα].  
 IT 501362-33-0P 501362-35-2P 501362-36-3P  
 501362-38-5P 501362-39-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and PPAR activating activity of: preparation of oxazole


diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-33-0 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)



RN 501362-35-2 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-36-3 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.

L12 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:202470 CAPLUS  
 DOCUMENT NUMBER: 138:238169  
 TITLE: Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators  
 INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schaefer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 Patent  
 DOCUMENT TYPE: German  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020269	A1	20030313	WO 2002-EP9221	20020817
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
CA 2458210	A1	20030313	CA 2002-2458210	20020817
AU 2002333456	A2	20030318	AU 2002-333456	20020817
EE 200400059	A	20040415	EE 2004-59	20020817
EP 1425014	A1	20040609	EP 2002-797589	20020817
EP 1425014	B1	20061213		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012158	A	20040713	BR 2002-12158	20020817
CN 1549713	A	20041124	CN 2002-817085	20020817
HU 200401564	A2	20041129	HU 2004-1564	20020817
JP 2005525294	T	20050825	JP 2003-524576	20020817
NZ 531440	A	20051028	NZ 2002-531440	20020817
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
NO 2004000811	A	20040519	NO 2004-811	20040224
BG 108598	A	20050331	BG 2004-108598	20040224
HK 1067560	A1	20060922	HK 2005-100116	20050107
PRIORITY APPLN. INFO.: DE 2001-10142734 A 20010831				
DE 2002-10223273 A 20020524				
WO 2002-EP9221 W 20020817				

OTHER SOURCE(S): MARPAT 138:238169  
 GI





AB The invention relates to diaryl cycloalkyl derivs. and their physiol. compatible salts and physiol. functional derivs. The invention also relates to oxazoles I [Z = C3-8-alkyl, C3-8-alkenyl (rings may contain 1 or more oxygens); R1, R2, R4, R5 = H, F, Cl, Br, OH, NO2, CF3, OCF3, Cl-6-alkyl, O-(Cl-6-alkyl); R3 = H, Cl-6-alkyl; X, Y = Cl-6-alkyl (chains may contain 1 or more oxygens)] to their physiol. compatible salts and to a method for producing the same. Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via O-alkylation with 4-(iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was determined [EC50 = 0.3 nM vs. PPARα].

IT 501362-33-0P 501362-35-2P 501362-36-3P  
501362-38-5P 501362-39-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and PPAR activating activity of; preparation of oxazole

diaryl cycloalkyl derivs. and the use thereof as PPAR activators)


RN 501362-33-0 CAPLUS  
CN Benzoic acid, 2-[[[3-[[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


RN 501362-35-2 CAPLUS  
CN Benzoic acid, 2-[[[3-[[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-36-3 CAPLUS  
CN Benzoic acid, 2-[[[3-[[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-38-5 CAPLUS  
CN Benzoic acid, 2-[2-[(1R,3R)-3-[[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-39-6 CAPLUS  
CN Benzoic acid, 2-[2-[(1R,3S)-3-[[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.